Efficacy News and Research

RSS

New class of drugs developed to treat cancer, reduces sudden cardiac death risk after heart attack

A researcher at the Cardiovascular Institute (CVI) at Rhode Island, The Miriam and Newport hospitals has found that a new class of drugs, originally developed to treat cancer, reduces sudden cardiac death risk after a heart attack. The findings were published online in advance of print in the Journal of the American College of Cardiology.

25 Feb 2014

Onset Dermatologics launches 75mg strength of MINOCIN pellet-filled capsules to treat bacterial infections

Onset Dermatologics, a leader in developing and commercializing prescription products for improving skin health, today announced the launch of a 75mg strength of MINOCIN (minocycline hydrochloride) Pellet-Filled Capsules.

25 Feb 2014

Policy statement suggests ways to improve drug safety and efficacy in children

With less than half of medications including specific labeling for children, Kathleen Neville, MD, MS, a physician at Children's Mercy Hospital, recently led an American Academy of Pediatrics (AAP) committee in updating the policy with new recommendations guiding the off-label use of drugs in pediatric patients.

24 Feb 2014

Blocking mechanisms for DNA repair may help to potentiate chemotherapy, says study

Chemotherapies are cancer treatments that work by inducing lesions in the DNA of tumour cells in order to inhibit their proliferation. However, the body naturally tries to repair these lesions, and thus reduces the efficacy of chemotherapy.

24 Feb 2014

IIN collaborates with Nanyang Technological University to establish Nanomedicine

Northwestern University's International Institute for Nanotechnology (IIN) is collaborating with Nanyang Technological University (NTU), Singapore, to establish the NTU-Northwestern Institute for Nanomedicine.

24 Feb 2014

REACT clinical trial provides valuable new insights for community gastroenterologists that benefit patients

The final results from an international clinical trial involving nearly 2,000 patients with Crohn's disease support the use of a new management strategy referred to as accelerated step-care as a best practice for the care of active Crohn's disease.

24 Feb 2014

New innovative technique can carry chemotherapy safely and release inside cancer cells

Researchers from the cancer nanotechnology and signal transduction and therapeutics programs of UCLA's Jonsson Comprehensive Cancer Center (JCCC) have developed an innovative technique that can carry chemotherapy safely and release it inside cancer cells when triggered by two-photon laser in the infrared red wave length.

24 Feb 2014

Social/behavioral intervention strategies may help drug users avoid injection-related HCV, HIV infections

Despite a number of social/behavioral intervention and educational programs, the spread of hepatitis C (HCV) in people who inject drugs (PWIDs) remains a chronic problem.

24 Feb 2014

LJPC completes dosing in Phase 2 clinical trial of GCS-100 for treatment of chronic kidney disease

La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the "Company" or "La Jolla"), a biotechnology company developing therapeutics targeting significant unmet, life-threatening diseases today announced that it has completed dosing of its Phase 2 clinical trial of GCS-100 for the treatment of chronic kidney disease ("CKD") and has collected the final data for evaluation of the primary endpoint.

23 Feb 2014

Altering sunitinib dosing schedule improves tolerability

Shortening the time that patients with advanced renal cell carcinoma are on and off treatment with sunitinib improves the drug’s overall tolerability without affecting its efficacy, say Japanese researchers.

21 Feb 2014

Advanced age should not preclude sunitinib use for mRCC

Elderly kidney cancer patients benefit from sunitinib therapy just as much as their younger counterparts, a retrospective analysis of six clinical trials shows.

21 Feb 2014

Humidification of mouth during radiotherapy reduces hospital stay, mucositis in head, neck cancer patients

Patients who received daily humidification of the mouth and throat region beginning from day one of radiation therapy treatment spent nearly 50 percent fewer days in the hospital to manage their side effects, according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium.

21 Feb 2014

CSL Behring enrolls first patient in phase III study of C1-INH for prevention of HAE attacks

CSL Behring today announced it has enrolled the first patient in COMPACT, an international phase III study of a volume-reduced, subcutaneous formulation of C1-esterase inhibitor oncentrate in patients with frequent hereditary angioedema attacks (NCT01912456).

20 Feb 2014

OrthoTrophix commences TPX-100 Phase 2 clinical study in knee osteoarthritis patients

OrthoTrophix, Inc., a privately held biopharmaceutical company, announced today that the Company started a Phase 2 clinical study of its cartilage repair therapeutic agent, TPX-100, with knee osteoarthritis patients in the U.S. The Company also announced that it had successfully closed the second and last tranche of its Series A preferred stock financing.

20 Feb 2014

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Pharmacyclics, Inc. today reported financial results and recent developments for the quarter and year ended December 31, 2013.

20 Feb 2014

Psychotherapies have specific effects on psychosis symptoms

There are small but robust differences in the effects of different psychotherapies on psychosis symptoms, say the authors of a meta-analysis.

20 Feb 2014

CardioCell announces new clinical trials using allogeneic stem-cell therapy to treat subjects with AMI

CardioCell LLC announces two new clinical trials using its allogeneic stem-cell therapy to treat subjects with acute myocardial infarction (AMI), a problem facing more than 1.26 million Americans annually.

20 Feb 2014

Nintedanib plus docetaxel shows second-line efficacy in recurrent NSCLC

Nintedanib plus docetaxel offers significant efficacy in patients with non-small-cell lung cancer who experience disease progression after first-line chemotherapy, phase III study results show.

19 Feb 2014

Omeros doses first patient in second Phase 2 clinical trial of OMS824

Omeros Corporation today announced dosing of the first patient in a second Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor being developed for the treatment of schizophrenia, Huntington's disease (HD) and other cognitive disorders. The Phase 2 trial will evaluate the tolerability, safety, pharmacokinetics and performance on a battery of tests in patients with symptomatic HD.

19 Feb 2014

Eleven Biotherapeutics announces first pivotal Phase 3 clinical study of EBI-005 for treatment of DED

Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that patient randomization and dosing are underway in the Company's first pivotal Phase 3 clinical study of EBI-005 for the treatment of moderate to severe dry eye disease (DED), the OASIS study (A Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Control In Subjects With Moderate to Severe Dry Eye Disease).

19 Feb 2014

Efficacy News and Research

New class of drugs developed to treat cancer, reduces sudden cardiac death risk after heart attack

Onset Dermatologics launches 75mg strength of MINOCIN pellet-filled capsules to treat bacterial infections

Policy statement suggests ways to improve drug safety and efficacy in children

Blocking mechanisms for DNA repair may help to potentiate chemotherapy, says study

IIN collaborates with Nanyang Technological University to establish Nanomedicine

REACT clinical trial provides valuable new insights for community gastroenterologists that benefit patients

New innovative technique can carry chemotherapy safely and release inside cancer cells

Social/behavioral intervention strategies may help drug users avoid injection-related HCV, HIV infections

LJPC completes dosing in Phase 2 clinical trial of GCS-100 for treatment of chronic kidney disease

Altering sunitinib dosing schedule improves tolerability

Advanced age should not preclude sunitinib use for mRCC

Humidification of mouth during radiotherapy reduces hospital stay, mucositis in head, neck cancer patients

CSL Behring enrolls first patient in phase III study of C1-INH for prevention of HAE attacks

OrthoTrophix commences TPX-100 Phase 2 clinical study in knee osteoarthritis patients

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Psychotherapies have specific effects on psychosis symptoms

CardioCell announces new clinical trials using allogeneic stem-cell therapy to treat subjects with AMI

Nintedanib plus docetaxel shows second-line efficacy in recurrent NSCLC

Omeros doses first patient in second Phase 2 clinical trial of OMS824

Eleven Biotherapeutics announces first pivotal Phase 3 clinical study of EBI-005 for treatment of DED

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News